Paradigm Biopharma (ASX:PAR) has officially kicked off its final-stage Phase 3 trial using injectable pentosan polysulfate sodium (iPPS) to treat patients with osteoarthritis (OA) in their knee joints, with randomised participants having now been dosed both at home in Australia and across the sea in the U.S.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more.This content has been prepared as part of a partne ...